Chronic treatment with fluphenazine alters parameters of oxidative stress in liver and kidney of rats

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 1, 2009, Pages 51-57

  Corte, Cristiane L Dalla ^a   Fachinetto, Roselei ^a   Puntel, Robson ^a   Wagner, Caroline ^a   Nogueira, Cristina W ^a   Soares, Félix A Antunes ^a   Rocha, João B T ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; DIPHENYL DISELENIDE; FLUFENAN; FLUPHENAZINE; PORPHOBILINOGEN SYNTHASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME ACTIVITY; KIDNEY HOMOGENATE; LIPID PEROXIDATION; LIVER HOMOGENATE; LIVER PROTECTION; LIVER TOXICITY; LONG TERM CARE; LONG TERM EXPOSURE; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

RATTUS;

EID: 84984535642     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00417.x     Document Type: Article

References (57)

1. Ozdemir V, Aklillu E, Mee S, Bertilsson L, Graham JE, Caligiuri M et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 2005 7 : 119 33.
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976 192 : 481 3.
3. Gunne LM, Andersson U, Bondesson U, Johansson P. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 1986 25 : 897 901. (Pubitemid 17179911)
4. See RE, Chapman MA, Klitenick MA. Chronic neuroleptic administration decreases extracellular GABA in the nucleus accumbens but not in the caudate-putamen of rats. Brain Res 1992 588 : 177 80.
5. Burger ME, Fachinetto R, Wagner C, Perottoni J, Pereira RP, Zeni G et al. Effects of diphenyl-diselenide on orofacial dyskinesia model in rats. Brain Res Bull 2006 70 : 165 70.
6. Cadet JL, Lohr JB, Jeste DV. Free radical and tardive dyskinesia. Trends Neurosci 1986 9 : 107 8.
7. Lohr JB, Cadet JL, Lohr MA, Larson L, Wasli E, Wade L. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988 14 : 291 6.
8. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990 28 : 535 9.
9. Ishak KG, Irey NS. Hepatic injury associated with the phenothiazines. Arch Pathol 1972 93 : 283 304.
10. Jones JK, Van de Carr SW, Zimmerman H, Leroy A. Hepatotoxicity associated with phenothiazines. Psychopharmacol Bull 1983 19 : 24 7.
11. Regal RE, Billi JE, Glazer HM. Phenothiazine-induced cholestatic jaundice. Clin Pharm 1987 10 : 787 94.
12. Munyon WH, Salo R, Briones DF. Cytotoxic effects of neuroleptic drugs. Psychopharmacology (Berl) 1987 91 : 182 8.
13. Zimmerman HJ. Spectrum of hepatotoxicity. Perspect Biol Med 1968 12 : 135 61.
14. Dujovne CA, Zimmerman HT. Cytotoxicity of phenothiazines on Chang liver cells as measured by enzyme leakage. Proc Soc Exp Biol Med 1969 131 : 583 7.
15. Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002 28 : 542 51.
16. Eghbal MA, Tafazoli S, Pennefather P, O'Brien PJ. Peroxidase catalysed formation of cytotoxic prooxidant phenothiazine free radicals at physiological pH. Chem Biol Interact 2004 151 : 43 51. (Pubitemid 39647936)
17. Mugesh G, du Mont WW, Sies H. Chemistry of biologically important synthetic organoselenium compounds. Chem Rev 2001 1001 : 2125 79.
18. Rayman MP. The importance of selenium to human health. Lancet 2000 356 : 233 41.
19. Klotz LO, Sies H. Defenses against peroxynitrite: selenocompounds and flavonoids. Toxicol Lett 2003 14 : 125 32.
20. Müller A, Gabriel H, Sies H. A novel biologically active selenoorganic compound protective glutathione-dependent effect of PZ 51 (Ebselen) against ADP-Fe-induced lipid peroxidation in isolated hepatocytes. Biochem Pharmacol 1985 34 : 1185 9.
21. Wendel A, Fausel M, Safayhi H, Tiegs G, Otter R. A novel biologically active seleno-organic compound-II. Activity of PZ 51 in relation to glutathione peroxidase. Biochem Pharmacol 1984 33 : 3241 5.
22. Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM. Ebselen protects both gray model of focal and white matter in a rodent cerebral ischemia. Stroke 2001 32 : 2149 56.
23. Moussaoui S, Obinu M, Daniel N, Reibaud M, Blanchard V, Imperato A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol 2000 166 : 235 45.
24. Porciúncula LO, Rocha JBT, Boeck CR, Vendite D, Souza DO. Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons. Neurosci Lett 2001 299 : 217 20.
25. Burger ME, Fachinetto R, Zeni G, Rocha JB. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav 2005 81 : 608 15.
26. Nogueira CW, Zeni G, Rocha JBT. Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem Rev 2004 104 : 6255 85.
27. Wilson SR, Zucker PA, Huang R-RC, Spector A. A development of synthetic compounds with glutathione peroxidase activity. J Am Chem Soc 1989 111 : 5936 9.
28. Meotti FC, Borges VC, Zeni G, Rocha JBT, Nogueira CW. Potential renal and hepatic toxicity of diphenyl diselenide, diphenyl ditelluride and ebselen for rats and mice. Toxicol Lett 2003 143 : 9 16. (Pubitemid 36412167)
29. Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Puntel RL, Paixão MW et al. Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats. Psychopharmacology (Berl) 2007 194 : 423 32.
30. Burger ME, Fachinetto R, Calegari L, Paixão MW, Braga AL, Rocha JBT. Effects of age on orofacial dyskinesia reserpine-induced and possible protection of diphenyl-diselenide. Brain Res Bull 2004 64 : 339 45.
31. Borges LP, Borges VC, Moro AV, Nogueira CW, Rocha JBT, Zeni G. Protective effect of diphenyl diselenide on acute liver damage induced by 2-nitropropane in rats. Toxicology 2005 210 : 1 8. (Pubitemid 40459637)
32. Borges LP, Nogueira CW, Panatieri RB, Rocha JBT, Zeni G. Acute liver damage induced by 2-nitropropane in rats: effect of diphenyl diselenide on antioxidant defenses. Chem Biol Interact 2006 160 : 99 107. (Pubitemid 43343914)
33. Barbosa NBV, Rocha JBT, Zeni G, Emanuelli T, Beque MC, Braga AL. Effect of organic forms of selenium on (-aminolevulinate dehydratase from liver, kidney and brain of adult rats. Toxicol Appl Pharmacol 1998 49 : 243 53.
34. Farina M, Barbosa NBV, Nogueira CW, Folmer V, Zeni G, Andrade LH et al. Reaction of diphenyl diselenide with hydrogen peroxide and inhibition of δ-aminolevulinate dehydratase from rat liver and cucumber leaves. Braz J Med Biol Res 2002 35 : 623 31.
35. Folmer V, Soares JC, Gabriel D, Rocha JBT. A high fat diet inhibits δ-aminolevulinate dehydratase and increases lipid peroxidation in mice (Mus musculus). J Nutr 2003 133 : 2165 70.
36. Soares JC, Folmer V, Rocha JBT. Influence of dietary selenium supplementation and exercise on thiol-containing enzymes in mice. Nutrition 2003 19 : 627 32.
37. Bechara EJH, Medeiros MHG, Monteiro HP, Hermes-Lima M, Pereira B, Demasi M et al. A free radical hypothesis of lead poisoning and in Born porphyrias associated with 5-aminolevulinic overload. Quim Nova 1993 16 : 385 92.
38. Bechara EJ. Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Braz J Med Biol Res 1996 29 : 841 51.
39. Emanuelli T, Pagel FW, Alves LB, Regner A, Souza DO. Inhibition of adenylate cyclase activity by 5-aminolevulinic acid in rat and human brain. Neurochem Int 2001 38 : 213 8.
40. Paulmier C. Selenoorganic functional groups In : Paulmier C (ed.). Selenium Reagents and Intermediates in Organic Synthesis. 1ed. Pergamon Press, Oxford, 1986 25 51.
41. 1A receptor function in a rodent model of tardive dyskinesia. Neuroscience 2000 101 : 629 35.
42. McCormick SE, Stoessl AJ. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Neuroscience 2003 119 : 547 55.
43. Burger MB, Fachinetto R, Wagner C, Perottoni J, Pereira RP, Zeni G et al. Effects of diphenyl diselenide on orofacial dyskinesia model in rats. Brain Res Bull 2006 70 : 165 70.
44. Ohkawa H, Ohishi H, Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979 95 : 351 8.
45. Sassa S. δ-Aminolevulinic acid dehydratase assay. Enzyme 1982 28 : 133 45.
46. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. J Biol Chem 1972 247 : 3170 5.
47. Aebi H. Catalase In : Bergmeyer HV (ed.). Methods of Enzymatic Analysis. VEB Chemie Weinheim 1974 673 7.
48. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 75.
49. Yang X, Kulkarni AP. Oxidation of phenothiazines by human term placental peroxidase in non-smokers. Teratog, Carcinog, Mutagen 1997 17 : 139 51.
50. Cheng HY, Sackett PH, McCreeny RL. Reactions of chlorpromazine cation radical with physiologically occurring nucleophiles. J Med Chem 1978 21 : 948 52.
51. Hammerich O, Parker VD. The kinetics and mechanisms of the reactions of cation radicals of phenothiazine-derivatives with acetate ion and water in acetonitrile. Acta Chem Scand, B, Org Chem Biochem 1983 37 : 303 11.
52. Tafazoli S, O'Brien PJ. Peroxidases: a role in the metabolism and side effects of drugs. Drug Discov Today 2005 10 : 617 25.
53. Cadet JL, Perumal AS. Chronic treatment with prolixine causes oxidative stress in rat brain. Biol Psych 1990 28 : 738 40.
54. Arteel GE, Sies H. The biochemistry of selenium and glutathione system. Environ Toxicol Pharmacol 2001 10 : 153 8.
55. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001 24 : 483 90.
56. McWilliam LJ. Drug-induced renal disease. Curr Diagn Pathol 2007 13 : 25 31. (Pubitemid 46150181)
57. Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psych Res 2003 37 : 43 51. (Pubitemid 35449770)